ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development.
Oncology drug development company’s new team members include Jay Feingold joins as CMO and head of oncology clinical development.
He has more than 25 years of industry, academic and medical experience and most recently worked as VP US medical affairs and chairman global medical affairs oversight committee at Daiichi Sankyo.
ADC has also appointed Michael Mulkerrin as head of CMC (chemistry manufacturing and control).
He has more than 20 years of industry experience in biologics manufacturing and recently work as VP process development and manufacturing at OncoMed and has had prior senior roles at Abgenix, Amgen and Genentech.
Additionally, Simon Chivers joins ADC as head of toxicology, Lisa Skelton is appointed as senior project manager for lead programme ADCT-301, Karin Havenith join as senior bioanalytical scientist, Francesca Zammarchi will work as cancer biologist, Dulce Gonclaves will serve as corporate counsel and Stephane Henchoz will be director of finance.
Michael Forer, CEO of ADC Therapeutics, said: “The quality of individuals and depth of experience that we have been able to attract demonstrates the significant potential for our PBD-based ADCs. This expansion underlines the progress we have made since the Company was established in early 2002.”